journal article·2013-03

The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin

Yuchen Fan, Wenwen Du, Bing He, Fengying Fu, Lan Yuan, Hounan Wu, Wenbing Dai, Hua Zhang, Xueqing Wang, Jiancheng Wang, Xuan Zhang, Qiang Zhang

Biomaterials· Volume 34· Issue 9
Publisher page

Abstract

Interstitial fluid pressure (IFP) in tumor is much higher than that in normal tissue and it constitutes a great obstacle for the delivery of chemodrugs, which makes it a potential target for cancer therapy. In this study, imatinib, a molecular targeting drug, was loaded in sterically stabilized liposomes (SSL-IMA) to reduce the tumor IFP, in an attempt to deliver more liposomal doxorubicin (SSL-DOX) into tumor tissue. In a mouse B16 melanoma model, intravenous injection of 20 mg/kg SSL-IMA achieved the most reduction of tumor IFP and the effect lasted for at least 50 h with the least hematotoxicity. However, intragastric administration of 100 mg/kg free IMA did not decrease the tumor IFP significantly. Mechanisms of the reduction of tumor IFP by SSL-IMA were proved to be the inhibition of PDGF receptor beta, the inhibition of tumor fibroblasts as well as the anti-angiogenesis effect of SSL-IMA. Then it was demonstrated by in vivo imaging that the decrease of tumor IFP by SSL-IMA led to a more and longer intratumoral distribution of the lipid vehicles. The improved delivery was proved again in the anti-tumor study. The combination of SSL-IMA and SSL-DOX inhibited tumor growth and induced apoptosis of tumor cells the most, at a low dose in which neither SSL-DOX nor SSL-IMA showed obvious anti-tumor efficacy. Since no synergy against B16 cells was found between SSL-IMA and SSL-DOX, it was clear that the improved combinational therapy was basically due to the decrease of tumor IFP by SSL-IMA. In conclusion, reducing tumor IFP by SSL-IMA seems to be a promising strategy to potentiate chemotherapies.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Chemotherapy-induced cardiotoxicity and mitigation · Angiogenesis and VEGF in Cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (41)

Show source-provided references
1. High interstitial fluid pressure - an obstacle in cancer therapy10.1038/nrc1456 ↗
2. Delivering nanomedicine to solid tumors10.1038/nrclinonc.2010.139 ↗
3. Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis10.2217/14796694.4.6.793 ↗
4. Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics10.1593/neo.09554 ↗
5. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells10.1016/j.biomaterials.2011.09.055 ↗
6. The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer10.1016/j.biomaterials.2012.08.031 ↗
7. Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy
8. A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma10.1007/s10637-006-9002-y ↗
9. Collagenase-1 injection improved tumor distribution and gene expression of cationic lipoplex10.1016/j.ijpharm.2011.12.015 ↗
10. TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model10.1007/s00595-009-4020-y ↗
11. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer10.1038/nm988 ↗
12. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors
13. Treatment with imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation10.1038/sj.bjc.6603366 ↗
14. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug10.1038/nrd839 ↗
15. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy
16. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts10.1038/sj.bjc.6603941 ↗
17. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models10.1021/mp1000235 ↗
18. Measurement of interstitial fluid pressure: comparison of methods10.1007/BF02584264 ↗
19. Sulforhodamine B colorimetric assay for cytotoxicity screening10.1038/nprot.2006.179 ↗
20. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies10.1124/pr.58.3.10 ↗
21. Differential effects of imatinib mesylate against uveal melanoma in vitro and in vivo10.1097/CMR.0b013e3283194118 ↗
22. Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy10.1158/0008-5472.CAN-04-3991 ↗
23. Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing10.1080/10428190600565057 ↗
24. STI571 enhances the therapeutic index of epothilone B by a tumor-selective increase of drug uptake
25. The myofibroblast in wound healing and fibrocontractive diseases10.1002/path.1427 ↗
26. Gene expression profiling reveals cross-talk between melanoma and fibroblasts: implications for host-tumor interactions in metastasis10.1158/0008-5472.CAN-04-0415 ↗
27. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting10.1371/journal.pmed.0050019 ↗
28. Imatinib mesylate inhibits platelet derived growth factor stimulated proliferation of rheumatoid synovial fibroblasts10.1016/j.bbrc.2006.06.052 ↗
29. PDGFRbeta and HIF-1alpha inhibition with imatinib and radioimmunotherapy of experimental prostate cancer10.4161/cbt.6.11.4854 ↗
30. A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier10.1016/j.jconrel.2010.03.018 ↗
31. Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics10.1016/j.drup.2005.03.004 ↗
32. Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate10.1158/0008-5472.CAN-03-1489 ↗
33. PDGF receptors as cancer drug targets10.1016/S1535-6108(03)00089-8 ↗
34. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors10.1158/0008-5472.CAN-04-0074 ↗
35. Nanoparticles for bioimaging10.1016/j.cis.2006.05.026 ↗
36. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes10.1016/j.jconrel.2011.03.014 ↗
37. How stealthy are PEG-PLA nanoparticles? An NIR in vivo study combined with detailed size measurements10.1007/s11095-011-0426-5 ↗
38. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft
39. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner10.1038/nnano.2012.45 ↗
40. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity10.1124/pr.56.2.6 ↗
41. Drug combination studies and their synergy quantification using the Chou-Talalay method10.1158/0008-5472.CAN-09-1947 ↗